| Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... New England Journal of Medicine 366 (15), 1382-1392, 2012 | 2198 | 2012 |
| Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials … A Du Bois, A Reuss, E Pujade‐Lauraine, P Harter, I Ray‐Coquard, ... Cancer 115 (6), 1234-1244, 2009 | 1883 | 2009 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised … E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ... The lancet oncology 18 (9), 1274-1284, 2017 | 1775 | 2017 |
| Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised … J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... The lancet oncology 15 (8), 852-861, 2014 | 1772 | 2014 |
| Olaparib plus bevacizumab as first-line maintenance in ovarian cancer I Ray-Coquard, P Pautier, S Pignata, D Pérol, A González-Martín, ... New England Journal of Medicine 381 (25), 2416-2428, 2019 | 1766 | 2019 |
| Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ... Nature genetics 45 (4), 371-384, 2013 | 662 | 2013 |
| Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial P Harter, A Bois, M Hahmann, A Hasenburg, A Burges, S Loibl, M Gropp, ... Annals of surgical oncology 13, 1702-1710, 2006 | 567 | 2006 |
| A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms P Harter, J Sehouli, D Lorusso, A Reuss, I Vergote, C Marth, JW Kim, ... New England Journal of Medicine 380 (9), 822-832, 2019 | 543 | 2019 |
| Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo … JA Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... The lancet oncology 17 (11), 1579-1589, 2016 | 501 | 2016 |
| GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer PDP Pharoah, YY Tsai, SJ Ramus, CM Phelan, EL Goode, K Lawrenson, ... Nature genetics 45 (4), 362-370, 2013 | 428 | 2013 |
| Incorporation of pazopanib in maintenance therapy of ovarian cancer A Du Bois, A Floquet, JW Kim, J Rau, JM Del Campo, M Friedlander, ... Journal of clinical oncology 32 (30), 3374-3382, 2014 | 389 | 2014 |
| Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission … P Harter, J Sehouli, A Reuss, A Hasenburg, G Scambia, D Cibula, ... International Journal of Gynecologic Cancer 21 (2), 2011 | 389 | 2011 |
| The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy LC Hanker, S Loibl, N Burchardi, J Pfisterer, W Meier, E Pujade-Lauraine, ... Annals of oncology 23 (10), 2605-2612, 2012 | 348 | 2012 |
| Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up A Oaknin, TJ Bosse, CL Creutzberg, G Giornelli, P Harter, F Joly, ... Annals of oncology 33 (9), 860-877, 2022 | 342 | 2022 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double … A Poveda, A Floquet, JA Ledermann, R Asher, RT Penson, AM Oza, ... The Lancet Oncology 22 (5), 620-631, 2021 | 339 | 2021 |
| The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications I Meinhold-Heerlein, C Fotopoulou, P Harter, C Kurzeder, A Mustea, ... Archives of gynecology and obstetrics 293, 695-700, 2016 | 336 | 2016 |
| Identification of six new susceptibility loci for invasive epithelial ovarian cancer KB Kuchenbaecker, SJ Ramus, J Tyrer, A Lee, HC Shen, J Beesley, ... Nature genetics 47 (2), 164-171, 2015 | 320 | 2015 |
| Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm … RL Coleman, D Lorusso, C Gennigens, A González-Martín, L Randall, ... The Lancet Oncology 22 (5), 609-619, 2021 | 303 | 2021 |
| Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases F Heitz, P Harter, HJ Lueck, A Fissler-Eckhoff, F Lorenz-Salehi, ... European journal of cancer 45 (16), 2792-2798, 2009 | 303 | 2009 |
| Treatment of recurrent ovarian cancer S Pignata, SC Cecere, A Du Bois, P Harter, F Heitz Annals of Oncology 28, viii51-viii56, 2017 | 293 | 2017 |
Andreas du BoisProfessor für Gynäkologie, Gutenberg Universität Mainz, Kliniken Essen MitteVerified email at kem-med.com
